Orchestra BioMed (OBIO) Expected to Post Earnings on Monday

Orchestra BioMed (NASDAQ:OBIO) is expected to release its Q3 2026 resultson Monday, November 9th. Analysts expect Orchestra BioMed to post earnings of ($0.40) per share and revenue of $0.13 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Orchestra BioMed (NASDAQ:OBIO) last released its earnings results on Monday, August 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.01. Orchestra BioMed had a negative net margin of 184.60% and a negative return on equity of 149.61%. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.14 million. On average, analysts expect Orchestra BioMed to post ($1.53) EPS for the current fiscal year and ($1.45) EPS for the next fiscal year.

Orchestra BioMed Price Performance

OBIO stock opened at $5.91 on Monday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 8.24 and a current ratio of 8.26. The firm has a 50 day moving average price of $5.70 and a 200-day moving average price of $4.54. Orchestra BioMed has a 52-week low of $3.46 and a 52-week high of $6.50. The firm has a market capitalization of $355.19 million, a price-to-earnings ratio of -6.95 and a beta of 0.56.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on OBIO shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Orchestra BioMed in a research report on Monday, October 5th. Weiss Ratings upgraded Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. B. Riley Financial boosted their target price on Orchestra BioMed from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Piper Sandler reissued an “overweight” rating on shares of Orchestra BioMed in a research note on Thursday, October 15th. Finally, Chardan Capital restated a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a report on Friday, October 23rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.17.

Insider Activity

In other news, insider Darren Sherman sold 15,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $4.94, for a total transaction of $74,100.00. Following the completion of the sale, the insider owned 1,134,402 shares of the company’s stock, valued at $5,603,945.88. This represents a 1.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was acquired at an average price of $4.79 per share, for a total transaction of $47,900.00. Following the completion of the transaction, the insider directly owned 1,070,746 shares of the company’s stock, valued at approximately $5,128,873.34. This trade represents a 0.94% increase in their position. The SEC filing for this purchase provides additional information. 7.50% of the stock is currently owned by corporate insiders.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization.

Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension.